Schweitzer Fachinformationen
Wenn es um professionelles Wissen geht, ist Schweitzer Fachinformationen wegweisend. Kunden aus Recht und Beratung sowie Unternehmen, öffentliche Verwaltungen und Bibliotheken erhalten komplette Lösungen zum Beschaffen, Verwalten und Nutzen von digitalen und gedruckten Medien.
Contributors and Authors with Unique Experiences in Rare Diseases Research and Orphan Products Development
Contributors include leading patient advocates, foundation leaders, research investigators, regulatory agency decision makers, and bio-pharmaceutical industry leaders
Multi-National Government Program and Policy Leaders
Manuel Posada, MD, PhD (Please expand as you feel appropriate) is a specialist in Internal Medicine and in Public Health and Preventive Medicine. He has considerable expertise in areas such as multivariate analyses, medical statistics and research methodology. In his current position as Director of the Institute of Rare Diseases Research (IIER), Institute of Health Carlos III he leads a broad range of rare diseases activities in Spain in areas such as epidemiological and public health research. Dr. Posada is also the Director of the National Biobank on Rare Diseases (ISCIII) and the National Rare Diseases Registry. Dr. Posada is an Independent expert of the Commission Expert Group of Rare Diseases (CEGRD), European Commission and a member of the Advisory Board of the European Commission Platform Rare Diseases Registration. He is currently the President of the International Conference of Orphan Drugs and Rare Diseases (ICORD)
Domenica Taruscio, M.D., is the Director of the Italian National Centre for Rare Diseases at the Italian National Institute of Health and of the National Rare Diseases Registry. She is a specialist in Histopathology and carried out post-doctoral studies in Human Genetics at Yale University (CT-USA) and in Bioethics. For decades, her efforts have been mainly directed to face the many and complex challenges posed by rare diseases and has addressed them from various facets: from science to society, from experimental research to public health, from training health professionals to the empowerment of patients and their families - having always at heart the quality of life of rare disease patients and of their families.
Stephen C. Groft, Pharm.D. is currently a Senior Advisor to the Director, National Center for Advancing Translational Sciences at the NIH, USA. He assisted in establishing the Office of Orphan Products Development at FDA in 1982 and served as the Director of NIH's Office of Rare Diseases Research from 1993-2014 stimulating rare diseases research and developing information for patients, health care providers, research investigators, the biopharmaceutical industry, and the public about rare diseases, ongoing and completed research and clinical trials, and patient advocacy groups. Numerous initiatives were established in this role including the establishment of the Genetic and Rare Diseases Information Center, the International Rare Diseases Research Consortium the International Conference on Rare Diseases and Orphan Drugs, the Rare Diseases Clinical Research Network, assisted in the development of the Undiagnosed Diseases Program at NIH and the global Undiagnosed Diseases Network International, and developed common data elements for patient registries. ORDR co-sponsored numerous scientific conferences to assist in identifying research priorities and developing research agendas for the investigation of rare diseases.
Part I Introduction.- Rare Diseases: Joining Mainstream Research and Treatment Based on Reliable Epidemiological Data.- Part II Rare diseases diagnosis.- Undiagnosed diseases: Italy-US collaboration and international efforts to tackle rare and common diseases lacking a diagnosis.- Intellectual disability & rare disorders: A diagnostic challenge.- Improved diagnosis and care for rare diseases through implementation of a precision public health framework.- Part III Registries, Natural History of Rare Diseases and Biobanks.- Natural history, trial readiness and gene discovery: advances in patient registries for neuromuscular disease.- Facilitating Clinical Studies in Rare Diseases.- Rare Diseases Biospecimens and patient registries: Interoperability for research promotion, a European example: EuroBioBank and Spain RDR-BioNER.- Data Quality in Rare Diseases Registries.- Preparing data at the source to foster interoperability across r
Dateiformat: PDFKopierschutz: Wasserzeichen-DRM (Digital Rights Management)
Systemvoraussetzungen:
Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Wasserzeichen-DRM wird hier ein „weicher” Kopierschutz verwendet. Daher ist technisch zwar alles möglich – sogar eine unzulässige Weitergabe. Aber an sichtbaren und unsichtbaren Stellen wird der Käufer des E-Books als Wasserzeichen hinterlegt, sodass im Falle eines Missbrauchs die Spur zurückverfolgt werden kann.
Weitere Informationen finden Sie in unserer E-Book Hilfe.